Evommune (EVMN) Operating Expenses (2024 - 2026)
Evommune (EVMN) posted quarterly Operating Expenses of $24.0 million for Q1 2026, up 32.84% year-over-year from $18.0 million in Q1 2025, and down 19.39% quarter-over-quarter from $29.7 million in Q4 2025.
Evommune (EVMN) Operating Expenses (2024 - 2026) Analysis & Trends
Evommune (EVMN) has reported Operating Expenses for 3 consecutive years, with $24.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Expenses rose 32.84% year-over-year to $24.0 million; the TTM figure through Mar 2026 stood at $95.0 million (changed N/A YoY), while the FY2025 annual figure was $94.1 million, up 22.15% from the prior year.
- Operating Expenses eased to $24.0 million in Q1 2026 per EVMN's latest filing, from $29.7 million in the prior quarter.
- Across five years, Operating Expenses topped out at $29.7 million in Q4 2025 and bottomed at $16.5 million in Q3 2024.
- Historically, Operating Expenses has averaged $22.2 million across 3 years, with a median of $22.4 million in 2024.
- Annual changes were most pronounced in 2025 — Operating Expenses soared 41.24% — and 2026, when it jumped 32.84%.
- Evommune's Operating Expenses stood at $21.5 million in 2024, then surged by 38.51% to $29.7 million in 2025, then retreated by 19.39% to $24.0 million in 2026.
- Business Quant data shows EVMN's Operating Expenses at $24.0 million in Q1 2026, $29.7 million in Q4 2025, and $23.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 2.89 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.21 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4,978.15 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 541.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.06 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 427.03 Mn |
| 10 | Evommune | 531.53 Mn | 330.73 Mn | - | 34.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 34.90 Mn |
| Mar 31, 2026 | 23.95 Mn |
| Dec 31, 2025 | 29.72 Mn |
| Sep 30, 2025 | 23.33 Mn |
| Mar 31, 2025 | 18.03 Mn |
| Dec 31, 2024 | 21.45 Mn |
| Sep 30, 2024 | 16.52 Mn |